ECHOSENS

Their core work

Echosens is a Paris-based medical device company and the developer of FibroScan, the leading commercial device for non-invasive liver assessment using Transient Elastography (TE) technology. Their core contribution to EU research is providing the TE measurement platform and clinical validation expertise for liver disease studies — enabling researchers and clinicians to measure liver stiffness and steatosis without biopsy. In H2020 projects, they appear as a technology partner whose proprietary device is the instrument of choice for large-scale liver screening and biomarker validation trials. Beyond hardware, they bring deep data on TE performance metrics, reference ranges, and screening protocols developed over years of commercial deployment across European clinical settings.

What they specialise in

How they've shifted over time

Echosens entered H2020 through LITMUS (2017) with a narrow focus on NAFLD biomarker validation — essentially testing whether their TE readings could predict or correlate with liver inflammation markers. By 2020, with LiverScreen, the scope broadened dramatically: the keywords shift from a single biomarker focus to a full screening ecosystem — fibrosis, cirrhosis, screening methodology, risk stratification, cost-effectiveness, and implementation. This reflects a maturation from pure technology validation toward real-world deployment science, suggesting Echosens is building the clinical and health-policy evidence base needed to make liver screening a standard-of-care recommendation across Europe.

Echosens is moving from device validation toward population-level screening advocacy, suggesting future collaboration opportunities in health policy, primary care integration, and digital health pathways for liver disease detection.

How they like to work

Echosens consistently joins as a participant, never as a project coordinator, which is typical for commercial technology providers who contribute a proprietary platform rather than managing research agendas. Their participation in consortia of 78 partners across 19 countries signals they are sought-after technology enablers — large academic and clinical consortia choose them because FibroScan is the field standard for non-invasive liver assessment. Working with them likely means gaining access to their device, reference data, and protocol expertise, in exchange for contributing to clinical evidence that strengthens their commercial position.

Echosens has collaborated with 78 unique partners across 19 countries, a notably wide network for just two projects, reflecting the large multi-site consortium structure of clinical validation trials like LITMUS and LiverScreen. Their reach is pan-European, spanning academic hospitals, research institutes, and clinical networks across the continent.

What sets them apart

Echosens occupies a rare position in EU health research: they are a commercial device manufacturer whose proprietary technology (FibroScan/TE) is the accepted reference method for a specific clinical measurement, making them a near-mandatory partner for any serious liver disease study. Unlike academic partners who contribute knowledge, Echosens contributes an irreplaceable instrument — researchers working on NAFLD, liver fibrosis, or cirrhosis screening need FibroScan data for their studies to be credible and comparable with the broader literature. For consortium builders, partnering with Echosens brings both the device and the implicit endorsement of clinical rigor their brand carries.

Highlights from their portfolio

• LITMUS
  One of the largest EU-funded NAFLD biomarker consortia (2017-2024), spanning 7 years and likely dozens of clinical sites, with Echosens providing the TE reference standard against which all competing biomarkers are benchmarked.
• LiverScreen
  The first pan-European population-based liver fibrosis screening study (2020-2025), positioning Echosens technology at the center of a potential public health policy shift toward routine liver screening across European countries.